These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9162244)

  • 21. [Prevention and depression of experimental allergic encephalomyelitis by the administration of brain antigens and barbamyl].
    Reber NV
    Patol Fiziol Eksp Ter; 1973; 17(1):65-7. PubMed ID: 4127854
    [No Abstract]   [Full Text] [Related]  

  • 22. [Suppression of experimental allergic encephalomyelitis with vaccinia-virus-induced anti-brain antibodies (author's transl)].
    Simon J; Hochstein-Mintzel V; Huber HC; Gradl A; Hansert E
    Z Immunitatsforsch Immunobiol; 1977 Apr; 153(1):23-35. PubMed ID: 68632
    [No Abstract]   [Full Text] [Related]  

  • 23. Experimental allergic encephalomyelitis: immunological properties of encephalitogenic polypeptides and proteins.
    Lamoureux G; Carnegie PR; McPherson TA; Johnston D
    Clin Exp Immunol; 1967 Sep; 2(5):601-9. PubMed ID: 4965043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dissociation of antibody production from disease suppression in the inhibition of allergic encephalomyelitis by myelin basic protein.
    Lisak RP; Falk GA; Heinze RG; Kies MW; Alvord EC
    J Immunol; 1970 Jun; 104(6):1435-46. PubMed ID: 4986769
    [No Abstract]   [Full Text] [Related]  

  • 25. Reaginic antibody in experimental allergic encephalomyelitis. II. Histamine and serotonin blockade.
    Moore MJ; Matthews JM; Matthews TK; Behan PO; Kies MW
    Res Commun Chem Pathol Pharmacol; 1974 Sep; 9(1):133-44. PubMed ID: 4140560
    [No Abstract]   [Full Text] [Related]  

  • 26. In vitro and in vivo immune responses to homologous myelin basic protein in experimental allergic encephalomyelitis.
    Lisak RP; Zweiman B
    Cell Immunol; 1974 Mar; 11(1-3):212-20. PubMed ID: 4141935
    [No Abstract]   [Full Text] [Related]  

  • 27. The onset of experimental allergic encephalomyelitis as defined by clinical, electro-physiological and immunochemical changes.
    Alvord EC; Shaw CM; Hruby S; Sires LR; Slimp JC
    Prog Clin Biol Res; 1984; 146():461-6. PubMed ID: 6201914
    [No Abstract]   [Full Text] [Related]  

  • 28. [Effect of nicotinamide on development of experimental allergic encephalomyelitis].
    Zhitnukhin IuL; Litvinenko IV; Ogurtsov RP
    Biull Eksp Biol Med; 1998 Feb; 125(2):180-2. PubMed ID: 9559132
    [No Abstract]   [Full Text] [Related]  

  • 29. Passive transfer of experimental allergic encephalomyelitis: mechanisms of suppression.
    Falk GA; Kies MW; Alvord EC
    J Immunol; 1969 Dec; 103(6):1248-53. PubMed ID: 5361563
    [No Abstract]   [Full Text] [Related]  

  • 30. Macrophage-mediated demyelination: the role of phospholipases and antibody.
    Trotter J; Smith ME
    Prog Clin Biol Res; 1984; 146():55-60. PubMed ID: 6201923
    [No Abstract]   [Full Text] [Related]  

  • 31. Neuroimmunology of multiple sclerosis and experimental allergic encephalomyelitis.
    Stuerzebecher S; Martin R
    Neuroimaging Clin N Am; 2000 Nov; 10(4):649-68 ,vii-viii. PubMed ID: 11359717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-encephalitogenic antigen-induced suppression and reversal of allergic encephalomyelitis.
    Hashim GA
    Nature; 1975 Aug; 256(5518):953-5. PubMed ID: 52118
    [No Abstract]   [Full Text] [Related]  

  • 33. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide.
    Teitelbaum D; Meshorer A; Hirshfeld T; Arnon R; Sela M
    Eur J Immunol; 1971 Aug; 1(4):242-8. PubMed ID: 5157960
    [No Abstract]   [Full Text] [Related]  

  • 34. Skin-fixing antibody in experimental allergic encephalomyelitis.
    Falk GA; Heinze RG; Kies MW; Alvord EC
    J Immunol; 1968 Feb; 100(2):321-8. PubMed ID: 5639700
    [No Abstract]   [Full Text] [Related]  

  • 35. [Influence of circulating antibodies on the formation of inflammatory reaction in allergic encephalomyelitis].
    Wajgt A
    Neuropatol Pol; 1973; 11(5):235-44. PubMed ID: 4759159
    [No Abstract]   [Full Text] [Related]  

  • 36. The temporal relationship of complement-fixing antibrain and tuberculin type sensitivity in experimental allergic encephalomyelitis.
    Greifenkamp J; Bartel AH; Fahlberg WJ
    Ann Allergy; 1970 Nov; 28(11):522-7. PubMed ID: 5521183
    [No Abstract]   [Full Text] [Related]  

  • 37. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion.
    Korn T; Magnus T; Toyka K; Jung S
    J Leukoc Biol; 2004 Nov; 76(5):950-60. PubMed ID: 15328336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic effects of cisplatin on rat experimental autoimmune encephalomyelitis.
    Li XB; Schluesener HJ
    Arch Immunol Ther Exp (Warsz); 2006; 54(1):51-3. PubMed ID: 16642257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Humoral autoimmune responses to neurospecific proteins in rats with experimental allergic encephalomyelitis and immunomodulation with allogeneic nervous tissue].
    Lisianyĭ MI; Liubych LD; Markova OV; Biel's'ka LM
    Fiziol Zh (1994); 2002; 48(1):15-24. PubMed ID: 11928626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Immunological studies of experimental allergic encephalomyelitis in juvenile guinea pigs. T cell subpopulations of peripheral blood and local infiltrating cells (author's transl)].
    Hirayama M; Sobue G; Takayanagi T; Iida M; Sobue I
    Rinsho Shinkeigaku; 1980 Feb; 20(2):81-7. PubMed ID: 6966206
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.